The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Will Be The Estimated Market Valuation Of The Sarcopenia Treatment Market By The End Of 2030?
The sarcopenia treatment market has experienced robust expansion in recent years. This market is expected to increase from $3.72 billion in 2025 to $3.94 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.9%. The growth witnessed during the historic period stems from factors such as an expanding elderly population base, greater understanding of age-related muscle deterioration, dependence on physical therapy and nutritional assistance, the restricted availability of approved pharmaceutical interventions, and an escalation in mobility-related conditions.
The sarcopenia treatment market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $4.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. This forecasted growth is largely driven by the emergence of new pharmacological therapies, a heightened emphasis on timely diagnosis and intervention, increased healthcare expenditure directed towards elderly care, the rising occurrence of chronic illnesses impacting muscle health, and the proliferation of clinical trials focused on muscle regeneration. Key developments expected during this period involve a greater uptake of combined pharmaceutical and exercise-driven approaches, the growing incorporation of nutritional supplements in managing sarcopenia, an increase in clinical investigations into myostatin inhibitors and anabolic agents, enhanced identification of sarcopenia among older adults, and the broader inclusion of physical therapy within treatment protocols.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13926&type=smp
What Drivers Are Shaping The Future Growth Of The Sarcopenia Treatment Market?
An anticipated increase in malnutrition is projected to drive the expansion of the sarcopenia treatment market in the future. Malnutrition encompasses an individual’s inadequate, excessive, or imbalanced consumption of energy and nutrients, including conditions like undernutrition, overweight, obesity, and diet-related noncommunicable illnesses. Sarcopenia treatments aim to tackle the concurrent issues of malnutrition and sarcopenia among elderly individuals using approaches like nutritional intervention and physical activity, with the goal of enhancing muscle mass, physical strength, and general nutritional well-being. As an illustration, a report released by the United States Department of Agriculture, a US-based government entity, indicated in January 2025 that household food insecurity affected 17.9% of families with children in 2023, impacting approximately 6.5 million similar households. Consequently, the increasing prevalence of malnutrition is fueling the development of the sarcopenia treatment market.
Which Segment Classifications Shape The Sarcopenia Treatment Market?
The sarcopenia treatment market covered in this report is segmented –
1) By Treatment Type: Protein Supplements, Vitamin B12 Supplements, Vitamin D And Calcium Supplements, Other Treatment Types
2) By Type: Primary Sarcopenia, Secondary Sarcopenia
3) By Route Of Administration: Oral, Parenteral, Enteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Protein Supplements: Whey Protein, Casein Protein, Soy Protein, Plant-Based Protein
2) By Vitamin B12 Supplements: Cyanocobalamin, Methylcobalamin
3) By Vitamin D And Calcium Supplements: Vitamin D2, Vitamin D3, Calcium Carbonate, Calcium Citrate
4) By Other Treatment Types: Exercise Programs, Hormone Replacement Therapy, Other Nutritional Interventions
What Major Market Trends Are Driving Changes In The Sarcopenia Treatment Market?
Leading entities within the sarcopenia treatment market are intensifying their efforts to develop various advanced clinical studies, aiming to provide improved treatment alternatives. A clinical study, by definition, involves a structured investigation with human participants to assess the safety, effectiveness, or results of a medical intervention. For example, in September 2023, Biophytis, a biotechnology firm based in France, received authorization from the Food and Drug Administration (FDA) to commence its SARA-31 Phase 3 study focusing on sarcopenia. This particular study is designed to assess the efficacy and safety of Sarconeos (BIO101) when used to treat sarcopenic individuals facing a risk of motor disability. It represents a notable leap forward in both technological and pharmaceutical treatment strategies, potentially delivering benefits in terms of efficacy and safety for patients suffering from severe sarcopenia. Notably, it marks the first Phase 3 study ever conducted for sarcopenia, having secured FDA authorization. Approximately 900 patients, all over 65 years old and presenting with sarcopenia, reduced walking speed, and diminished hand grip strength, will participate in the study. The main objective, or primary endpoint, involves evaluating the risk of major mobility disability (MMD), along with walking speed, hand grip strength, and the patients’ self-reported quality of life.
Which Companies Are Expanding Their Footprint In The Sarcopenia Treatment Market?
Major companies operating in the sarcopenia treatment market are Pfizer Inc, F Hoffmann La Roche, Merck Sharp And Dohme Corp, AbbVie Inc, Bayer AG, Novartis AG, Sanofi SA, Abbott Laboratories Inc, GlaxoSmithKline plc, Eli Lilly And Company, BASF SE, Nestle Health Science, Haleon Group Of Companies, DSM, Amway Corporation, Perrigo Company PLC, Intas Pharmaceuticals Ltd, Zydus Lifesciences, Fermenta Biotech Limited, Metagenics LLC, Makers Nutrition LLC, NutraScience Labs, AstaReal AB, NutraPak USA, BioThrive Sciences, Wellona Pharma, Healing Pharma India Pvt Ltd, Nutrafill
Read the full sarcopenia treatment market report here:
https://www.thebusinessresearchcompany.com/report/sarcopenia-treatment-global-market-report
Which Geographic Regions Are Influencing Demand In The Sarcopenia Treatment Market?
North America was the largest region in the sarcopenia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sarcopenia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Sarcopenia Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=13926&type=smp
Browse Through More Reports Similar to the Global Sarcopenia Treatment Market 2026, By The Business Research Company
Sarcoma Drugs Global Market Report
https://www.thebusinessresearchcompany.com/report/sarcoma-drugs-global-market-report
Congenital Diaphragmatic Hernia Drugs Global Market Report
Vulvodynia Treatment Global Market Report
https://www.thebusinessresearchcompany.com/report/vulvodynia-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model